Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.65 EUR -2.99% Market Closed
Market Cap: 14.7m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

Net Margin
Celyad Oncology SA

-10 766.7%
Current
-12 663%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-10 766.7%
=
Net Income
-7.8m
/
Revenue
72k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
BE
Celyad Oncology SA
XBRU:CYAD
14.7m EUR
-10 767%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
150.5B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-14%
Country BE
Market Cap 14.7m EUR
Net Margin
-10 767%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 320.1B USD
Net Margin
9%
Country US
Market Cap 150.5B USD
Net Margin
13%
Country US
Market Cap 120.4B USD
Net Margin
-5%
Country US
Market Cap 113.8B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.4B AUD
Net Margin
18%
Country US
Market Cap 82.9B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.5B EUR
Net Margin
-14%
No Stocks Found

Celyad Oncology SA
Glance View

Market Cap
14.7m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

CYAD Intrinsic Value
0.03 EUR
Overvaluation 96%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-10 766.7%
=
Net Income
-7.8m
/
Revenue
72k
What is the Net Margin of Celyad Oncology SA?

Based on Celyad Oncology SA's most recent financial statements, the company has Net Margin of -10 766.7%.